ClinicalTrials.gg
CompletedNCT00195819Updated Jun 28, 2011Results posted

Safety and Efficacy of Adalimumab in Patients With Active Ankylosing Spondylitis

A Phase 3 interventional study of adalimumab (D2E7) and placebo in Ankylosing Spondylitis, sponsored by Abbott. Completed at 9 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-06-28.

Sponsored by Abbott · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 19 studies testing adalimumab in Spondylitis, Ankylosing — 2 open to participants now, 3 under way, none of them phase 3. Adalimumab · Spondylitis, Ankylosing.

Enrollment
9th of 19
82 · median 80
Started
2003
the only one that year
Phase 3
7 of 19
none open now
Registered
2nd of 19
by date
Lead sponsor
5 of 19
Abbott

Among the 19 studies testing adalimumab in Spondylitis, Ankylosing, this one is the 9th largest by enrollment, is the only one that started in 2003, is one of 7 in phase 3, and was the 2nd registered.

Spondylitis, Ankylosing

533 studies on the registry are indexed under Spondylitis, Ankylosing; 98 are open to participants now.

Browse Spondylitis, Ankylosing studies →

Open to participants now

2 of the 19 studies testing adalimumab in Spondylitis, Ankylosing are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 62 Spondylitis, Ankylosing studies recruiting now, 24 (39%) set no upper age limit and 32 (52%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing adalimumab in Spondylitis, Ankylosing, or all of them as a file.
02

Study summary

The purpose of the study is to assess the safety and clinical efficacy of adalimumab in subjects with active ankylosing spondylitis

03

Conditions studied

  • Ankylosing Spondylitis

Keywords

  • ankylosing spondylitis
  • adalimumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject was age 18 or older and in relatively good health (Investigator discretion) with a recent stable medical history.
  • Subject met the definition of AS based on the Modified New York Criteria.
  • Subject had an inadequate response to or intolerance to one or more NSAIDs as defined by the Investigator

Exclusion criteria

Exclusion Criteria:

  • Subject had previously received anti-TNF therapy.
  • Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study
  • Female subject who is pregnant or breast-feeding or considering becoming pregnant
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
82 participants (actual)

Study arms

  • Experimental
    Adalimumab

    Biological: adalimumab (D2E7)

  • Placebo comparator
    Placebo

    Biological: placebo

Interventions

  • Adalimumab 40 mg every other week (eow)

    Also known as: ABT-D2E7, adalimumab, Humira

  • Biologicalplacebo

    Placebo every other week (eow)

06

What researchers measure

Primary outcomes

  1. Number of Subjects With a Reduction in Signs and Symptoms as Measured by Assessments of Ankylosing Spondylitis (ASAS) 20 Response at Week 12

    ASAS 20 responders - improvement of \>=20% and absolute improvement of \>=10 units from Baseline in a visual analog scale (VAS) 0 \[no disease activity\]-100 \[high disease activity\]) for \>=3 of 4 domains; Patient's Global Assessment of disease activity VAS; (0\[none\]-100 \[severe\]), Total Back Pain VAS; (0 \[no pain\]-100 \[severe\]), BAth Ankylosing Spondylitis Functional Index (BASFI) VAS (0 \[easy \]-100\[impossible\]); and Inflammation VAS; (1 \[no pain\] to 10 \[severe pain\]) and absence of deterioration in the potential remaining domain. Applied to each scale and not to an overall global scale.

    Time frame: Week 12

  2. Mean Change in the Modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) Compared Against a Historical Control Group (Outcomes in Ankylosing Spondylitis International Study [OASIS]) Using the ANCOVA Model Adjusting for Baseline mSASSS Score

    Radiographic progression was based on change in mSASSS scoring (comparison of the means) from double-blind Baseline visit to Week 104. The mSASSS is the sum of the lumbar and cervical spine score ( 0 \[no change\] to 72 \[progression\]), derived from scoring the anterior site of the lumbar spine (T12 to S1) and the cervical spine (C2 to T1) as either 0 (normal), 1 (erosion, sclerosis, or squaring), 2 (syndesmophyte), 3 (bridging syndesmophyte), or N (vertebral body not evaluable). Data from NCT00195819 was compared with data from AS patients in OASIS.

    Time frame: Baseline and Week 104

Secondary outcomes

  1. Number of Subjects With a Reduction of Signs and Symptoms as Measured in Assessments of Ankylosing Spondylitis (ASAS) 20 - Through Week 260 of Adalimumab Exposure

    ASAS 20 responders - improvement of \>=20% and absolute improvement of \>=10 units from Baseline in a visual analog scale (VAS) 0 \[no disease activity\]-100 \[high disease activity\]) for \>=3 of 4 domains; Patient's Global Assessment of disease activity VAS; (0\[none\]-100 \[severe\]), Total Back Pain VAS; (0 \[no pain\]-100 \[severe\]), BASFI VAS (0 \[easy \]-100\[impossible\]); and Inflammation VAS; (1 \[no pain\] to 10 \[severe pain\]) and absence of deterioration in the potential remaining domain. Applied to each scale and not to an overall global scale

    Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260

  2. Number of Subjects With a Reduction of Signs and Symptoms as Measured by Assessments in Ankylosing Spondylitis (ASAS) ASAS 50 Through Week 260 of Adalimumab Exposure

    ASAS 50 responders - improvement of \>=50% and absolute improvement of \>=20 units (0-100) from Baseline in visual analog scale (VAS) for \>=3 of the 4 domains; Patient's Global Assessment of disease activity; (0\[none\]-100\[severe\]) VAS scale; Total Back Pain VAS; (0 \[no pain\]-100 \[severe\]); BASFI VAS; (0 \[easy \]-100\[impossible\]) and Inflammation VAS; (1 \[no pain\] to 10 \[severe pain\]). In addition, absence of deterioration in the potential remaining domain. Applied to each scale and not overall global scale.

    Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260

  3. Number of Subjects With a Reduction of Signs and Symptoms as Measured in Assessments of Ankylosing Spondylitis (ASAS) ASAS 70 Through Week 260 of Adalimumab Exposure

    ASAS 70 responders - improvement of \>=70% and absolute improvement of \>=30 units (0-100) from Baseline in visual analog scale (VAS) for \>=3 of the 4 domains; Patient's Global Assessment of disease activity VAS; (0\[none\]-100\[severe\]) Total Back Pain VAS; (0 \[no pain\]-100 \[severe\]); BASFI VAS; (0 \[easy \]-100\[impossible\]) and Inflammation VAS; 1 \[no pain\] to 10 \[severe pain\]). In addition, absence of deterioration in the potential remaining domain. Applied to each scale and not to an overall global scale.

    Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260

  4. Mean Change in Patient's Global Assessment of Disease Activity in Subjects With Adalimumab Exposure Through Week 260

    Evaluation of the effect of adalimumab 40 mg every other week (eow) on patient's global assessment of disease activity. The patient was to assess his/her disease activity in the past week using a visual analog scale (VAS) on a scale of 0 to 100 mm with no activity being indicated by 0 and severe activity by 100.

    Time frame: Weeks 12, 24, 36, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260

  5. Number of Subjects With a Reduction of Signs and Symptoms as Measured in Patient's Global Assessment of Disease Activity (an Individual Component of ASAS 20) Through Week 260 of Adalimumab Exposure

    The patient assesses his/her disease activity for the past week using a Patient Global Assessment of Disease on visual analog scale (VAS) with 0 being none and 100 being severe.

    Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260

  6. Mean Change in the Bath Ankylosing Spondylitis Functional Index (BASFI) in Subjects With Adalimumab Exposure Through Week 260

    BASFI consist of a set of 10 questions designed to determine the degree of functional limitation in subjects with AS. The BASFI score was derived based on the average of questions 1 through 10. The first 8 questions considered activities related to functional anatomy and the final 2 questions assessed the subject's ability to cope with everyday life over the last week. A 10 cm visual analog scale (VAS) was used to answer the questions and the mean of the ten scales gave the BASFI score a value between 0 (easy) and 10 (impossible).

    Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 232, 244, and 260

  7. BASFI (an Individual Component of ASAS 20) Through Week 260 of Adalimumab Exposure

    BASFI consisted of 10 Visual Analog Scale (VAS) questions with a response ranging from 0 (easy) to 100 (impossible). The BASFI score was derived based on the average of questions 1 through 10. A responder is a subject who demonstrates an absolute improvement of at least 10 units and a percentage improvement of at least 20% from Baseline.

    Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260

  8. Mean Change in Total Back Pain Visual Analog Scale (VAS) in Subjects With Adalimumab Exposure Through Week 260

    Evaluation of the effect of 40 mg every other week (eow) adalimumab on Total Back Pain VAS. The subject was to assess his/her disease activity in the past week using a total spine VAS on a scale 0 (no pain) to 100 (severe pain).

    Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260

  9. Total Back Pain (an Individual Component of ASAS 20) Through Week 260 of Adalimumab Exposure

    A responder is a subject who demonstrates an absolute improvement of at least 10 units and a percentage improvement of at least 20% from Baseline.

    Time frame: Weeks 12, 24, 52, 76, 128, 152, 180, 208, 220, 232, 244, and 260

  10. Mean Change in Inflammation (Mean of BASDAI Questions 5 and 6) in Subjects With Adalimumab Exposure Through Week 260

    The inflammation score is the mean of the two morning stiffness-related BASDAI visual analog scale (VAS) scores (items 5 and 6 of the BASDAI) of 0 (none) to 10 (very severe). A decrease in inflammation represents improvement.

    Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260

  11. Inflammation (Individual Component of ASAS 20) (Mean of BASDAI Questions 5 and 6) Through Week 260 of Adalimumab Exposure

    A responder is a subject who demonstrates an absolute improvement of at least 10 units and a percentage improvement of at least 20% from Baseline in inflammation (mean of the BASDAI questions 5 and 6 on scale of 0 \[none\] to 10 \[very severe\].

    Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260

  12. Number of Subjects With a Reduction of Signs and Symptoms as Measured in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 20 Through Week 260 of Adalimumab Exposure

    The BASDAI is a questionnaire with 6 questions that subject completes by marking answers on a 10-cm Visual Analog Scale (VAS) during the last week with responses that range from 0 (none) to 100(very severe) and measures severity of fatigue, spinal and peripheral joint pain, localized tenderness and morning stiffness. The final BASDAI score ranges from 0 (none) to 10 (very severe). Improvement in BASDAI by 20% was assessed. BASDAI Scoring: 1. Measure each item of the BASDAI in centimeters (out of a total of 10) 2. BASDAI Score = 0.2 (Item 1 + Item 2 + Item 3 + Item 4 + Item 5/2 + Item 6/2).

    Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260

  13. Number of Subjects With a Reduction of Signs and Symptoms as Measured in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 Through Week 260 of Adalimumab Exposure

    The BASDAI is a questionnaire with 6 questions that subject completes by marking answers on a 10-cm Visual Analog Scale (VAS) during the last week with responses that range from 0 (none) to 100 (very severe) and measures severity of fatigue, spinal and peripheral joint pain, localized tenderness and morning stiffness. The final BASDAI score ranges from 0 to 10. Improvement in BASDAI by 50% was assessed. BASDAI Scoring: 1. Measure each item of the BASDAI in centimeters (out of a total of 10) 2. BASDAI Score = 0.2 (Item 1 + Item 2 + Item 3 + Item 4 + Item 5/2 + Item 6/2).

    Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260

  14. Number of Subjects With a Reduction of Signs and Symptoms as Measured in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 70 Through Week 260 of Adalimumab Exposure

    The BASDAI is a questionnaire with 6 questions that subject completes by marking answers on a 10-cm Visual Analog Scale (VAS) during the last week with responses that range from 0 (none) to 100 (very severe) and measures severity of fatigue, spinal and peripheral joint pain, localized tenderness and morning stiffness. The final BASDAI score ranges from 0 to 10. Improvement in BASDAI by 70% was assessed. BASDAI Scoring: 1. Measure each item of the BASDAI in centimeters (out of a total of 10) 2. BASDAI Score = 0.2 (Item 1 + Item 2 + Item 3 + Item 4 + Item 5/2 + Item 6/2).

    Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260

  15. Mean Change in BASDAI in Subjects With Adalimumab Exposure Through Week 260

    The BASDAI is a questionnaire with 6 questions that subject completes by marking answers on a 10-cm Visual Analog Scale (VAS) during the last week with responses that range from 0 (none) to 100 (very severe) and measures severity of fatigue, spinal and peripheral joint pain, localized tenderness and morning stiffness. The final BASDAI score ranges from 0 (none) to 10 (severe). A decrease in BASDAI represents improvement. BASDAI Scoring: 1) Measure each item of the BASDAI in centimeters (out of a total of 10) 2) BASDAI Score = 0.2 (Item 1 + Item 2 + Item 3 + Item 4 + Item 5/2 + Item 6/2).

    Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260

  16. Mean Change in C-Reactive Protein (CRP) (mg/dL) in Subjects With Adalimumab Exposure Through Week 260

    Evaluation of the mean changes in CRP in subjects with adalimumab exposure from Baseline through 5 years. The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation via the use of an ultrasensitive assay. A decrease in the level of CRP indicate reduction in inflammation. A decrease in CRP indicates improvement.

    Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260

  17. Number of Subjects With a Disease Controlling Clinical Response From Adalimumab as Measured in Assessments of Ankylosing Spondylitis (ASAS) 40 - Through Week 260 of Adalimumab Exposure

    ASAS 40 responder: improvement of \>= 40% and absolute improvement of \>= 20 units (on a scale of 0 to 100) in \>= 3 of the 4 domains: Patient global assessment (VAS score \[0-100 scale\]); Pain (Total Back Pain VAS score 0-100 scale); Function (BASFI score 0-100 scale); Inflammation (the mean of the two morning stiffness-related BASDAI VAS scores (i.e. the average of items 5 and 6 of the BASDAI. Applied to each scale. In addition, absence of deterioration in the potential remaining domain, where deterioration is defined as a net worsening of \> 0 units (on a scale of 0 to 100).

    Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244 and 260

  18. Number of Subjects With a Disease Controlling Clinical Response From Adalimumab as Measured in Assessments of Ankylosing Spondylitis Ankylosing Spondylitis (ASAS) 5/6 in Subjects With Adalimumab Exposure Through Week 260

    The change in ASAS 5/6 was evaluated for the effect of adalimumab on structural damage. ASAS 5/6 criteria is the 20% improvement in 5 out of 6 domains (physical function \[BASFI\], Total Back Pain, Patient's Global Assessment of Disease Activity, Inflammation \[mean of Questions 5 and 6 of the BASDAI\], spinal mobility \[BASMI\], and acute phase reactants \[CRP\]).

    Time frame: Weeks 12, 16, 20, 24, 30, 36, 42, 48, 52, 64, 76, 88, 104, 116, 128, 140, 156, 168, 180, 192, 208, 220, 232, 244, and 260

  19. Number of Subjects With a Disease Controlling Clinical Response From Adalimumab as Measured in Partial Remission Response in Subjects With Adalimumab Exposure Through Week 260

    Evaluation of the mean changes in BASDAI in subjects with adalimumab exposure from Baseline through 5 years for the effect of adalimumab on structural damage. Partial remission was calculated as follows: A value below 20 on a 0 - 100-point scale in each of the four domains of the ASAS (Patient's Global Assessment of Disease Activity, Pain, Function and Inflammation). Partial remission is also regarded as a low disease activity state.

    Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260

  20. Mean Change in the Bath Ankylosing Spondylitis Metrology Index (BASMI) in Subjects With Adalimumab Exposure Through Week 260

    BASMI measures the range of motion based on five clinical measurements: 1) cervical rotation, 2) tragus to wall distance, 3) lumbar side flexion, 4) lumbar flexion (modified Schober's) and 5) intermalleolar distance. BASMI 0 = indicates mild disease involvement, 1 = moderate disease, and 2 = severe disease involvement. The results for cervical rotation and lumbar side flexion are the means of the left and right measurements. Scoring range 0-10. The higher the BASMI score, the more severe was the subject's limitation of movement due to their AS.

    Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260

  21. Mean Change in Edmonton Ankylosing Spondylitis Metrology Index (EDASMI) in Subjects With Adalimumab Exposure Through Week 260

    The EDASMI is a composite spinal mobility index comprised of 4 measures: 1) cervical rotation, 2) lumbar side flexion, 3) chest expansion, and 4) hip internal rotation spread. A grade of 0-4 scoring system was developed for each of the measures. The sum of 4 items (range 0 to 16) provide the EDASMI score. Decrease in EDASMI represents improvement. All EDASMI measures were done with a simple tape measure and recorded in centimeters (cm) by a rheumatologist and a clinician nurse.

    Time frame: Weeks 12, 24, 52, 104, 128, 156, 180, 208, 220, 232, 244, and 260

  22. Mean Change in Chest Expansion (CE) in Subjects With Adalimumab Exposure Through Week 260

    The patient is in a sitting position on the examination table with the hands on the hips. A pen mark is made at the xiphisternum and a tape measure placed around the circumference of the patient's chest at this level. The patient is asked to take a deep breath and to exhale as completely as possible while looking directly ahead. The measurement (in cm) is noted. The patient is asked to inhale as deeply as possible and the measurement (in cm) is noted. The difference in the 2 measurement points (in cm) constitutes the value for CE. An increase in chest expansion represents improvement

    Time frame: Weeks 12, 24, 52,104, 128, 156, 180, 208, 220, 232, 244, and 260

  23. Mean Change in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) in Subjects With Adalimumab Exposure Through Week 260

    MASES is measured by scoring of entheses of 0 (no tenderness) to 3 (severe tenderness) at 13 sites on the body. The score was derived as the sum of the 13 scores divided by 3 and the total range is 0 (no tenderness) to 13 (severe tenderness).

    Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 232, and 260

  24. Mean Change in the Bath Ankylosing Spondylitis Global Index (BAS-G) in Subjects With Adalimumab Exposure Through Week 260

    BAS-G consisted of two questions that asked the subject to indicate, on a 10 cm VAS, the effect the disease had on their well being over 1) last week, and 2) last 6 months. BAS-G was measured by two VAS scores (0 to 100 mm) to reflect the effect of Ankylosing Spondylitis on subject's well-being over the past week and over the last 6 months, respectively. The average of these two scores was reported. The mean of the two scores give a BAS-G score of 0-10.

    Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260

  25. Mean Change in Swollen Joint Count for 44 Joints (44 SJC) in Subjects With Adalimumab Exposure Through Week 260

    Change from Baseline in the swollen joint index. An assessment of 44 joints for SJC done by physical examination. Joint swelling was classified as present ("1"), absent ("0") or injected/replaced ("9"). The joints assessed were: Sternoclavicular, Acromioclavicular, Shoulder, Elbow, Wrist, Metacarpophalangeal (1-5), Thumb interphalangeal, Proximal interphalangeal (2-5, Knee, Ankle, and Metatarsophalangeal (1-5).

    Time frame: Weeks 12, 24, 36, 52, 76, 104, 128, 156, 180, 208, 232, and 260

  26. Mean Change From Baseline in the Tender Joint Count for 46 Joints (TJC 46) in Subjects With Adalimumab Exposure Through Week 260 of Adalimumab Exposure

    Assessment of 46 joints for TJC was done by physical examination. Joint tenderness was classified as present ("1"), absent ("0") or injected/replaced ("9"). The joints assessed were: Sternoclavicular, Acromioclavicular, Shoulder, Elbow, Wrist, Metacarpophalangeal (1-5), Thumb interphalangeal, Proximal interphalangeal (2-5, Knee, Ankle, and Metatarsophalangeal (1-5).

    Time frame: Weeks 12, 24, 36, 52, 76, 104, 128, 156, 180, 208, 232, and 260

  27. Mean Change in Physician's Global Assessment of Disease Activity in Subjects With Adalimumab Exposure Through Week 260

    The physician will globally assess the subject's current disease state using a VAS scale with 0 being very good and 100 being very bad.

    Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260

  28. Mean Change in Nocturnal Pain in Subjects With Adalimumab Exposure Through Week 260

    The subject was to assess his/her nocturnal pain intensity for the past week using a Nocturnal Pain Visual Analog Scale (Nocturnal Pain VAS). The range was 0 to 100 mm with no pain being indicated by 0 and worse possible pain by 100.

    Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260

  29. Mean Change in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale in Subjects With Adalimumab Exposure Through Week 260

    The FACIT-Fatigue scale: overall score of 13 general questions divided into four primary Quality of Life (QoL) domains: 1) Physical Well-Being, 2) Social/Family Well-Being, 3) Emotional Well-Being, and 4) Functional Well-Being. For each question subject rates his/her condition for the past week on a 5-point scale ranging from 0 (not at all) to 4 (very much). The score ranges from 0 (highest level of fatigue) to 52 with 52 being the lowest level of fatigue.

    Time frame: Baseline and at Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 232, and 260

  30. Mean Change in the SF-36 Health Survey Index Physical Component Summary [PCS] Through Week 260 of Adalimumab Exposure

    Change from Baseline in the SF-36 Health Survey Index completed by Subject to help subject keep track of how he/she was feeling and how well he/she was able to do usual activities. Components of the SF-36 included the PCS and MCS, respectively. An increase in SF-36 PCS or MCS indicate improvement.

    Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 232, and 260

  31. Number of Subjects With SF-36 Physical Component Summary (PCS) of Minimal Clinically Important Difference (MCID) Response Through Week 260 of Adalimumab Exposure

    SF-36 is a standardized survey evaluating 8 aspects of functional health and well being; physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, and mental health. The score for a section is an average of the individual question scores, which are scaled 0(no functioning)to 100 (highest level of functioning). Responders were subjects with MCID \> 3 points. Minimal clinically important difference (MCID) for PCS was determined by a \>= 3.0 point increase during exposure to adalimumab.

    Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 232, and 260

  32. Mean Change in the SF-36 Health Survey Index Mental Component Summary [MCS] Through Week 260 of Adalimumab Exposure

    SF-36 is a standardized survey evaluating 8 aspects of functional health and well being; physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, and mental health. The score for a section is an average of the individual question scores, which are scaled 0 (no functioning) to 100 (highest level of functioning). Change from Baseline in the SF-36 Health Survey Index was completed by Subject. Components of the SF-36 included the PCS and MCS, respectively. An increase in SF-36 PCS or MCS indicated improvement.

    Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 232, and 260

  33. Number of Subjects With SF-36 Mental Component Summary (MCS) of Minimal Clinically Important Difference (MCID) Response Through Week 260 of Adalimumab Exposure

    SF-36 is a standardized survey completed by Subject, evaluating 8 aspects of functional health and well being; physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, and mental health. The score for a section is an average of the individual question scores, which are scaled 0 (no functioning) to 100 (highest level of functioning). Responders are subjects with MCID \> 3 points. Minimal clinically important difference (MCID) for PCS was determined by a \>= 3.0 point increase during exposure to adalimumab.

    Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 232, and 260

  34. Mean Change in Health Utilities Index-3 (HUI-3) Through Week 260 of Adalimumab Exposure

    Change from baseline in Health Utility Index Mark 3 (HUI-3) was reported. The HUI-3 is a generic approach to the measurement of health status and assessment of HRQL. The HUI-3 was comprised of two complementary components. The first component was a multi-attribute health status classification system that was used to describe health status. The second component was a multi-attribute utility function that was used to value health status as measured within the corresponding multi-attribute health status classification system. An increase in the HUI-3 score represents improvement.

    Time frame: Weeks 24, 52, 104, 128, 156, 180, 208, 232, and 260

  35. Mean Change in the Ankylosing Spondylitis Quality of Life Questionaire (ASQoL) in Subjects Through Week 260 of Adalimumab Exposure

    ASQoL determined subject's quality of life and is comprised of 18 questions (yes or no) to be completed by the subject. Each statement on the ASQoL is given a score of "1" or "0." All item scores were summed to give a total score or index. Total scores ranged from 0 (good quality of life) to 18 (poor quality of life) related to ability to cope, relationships, mood, sleep, motivation, activities of everyday living, independence, and social life. Decrease in ASQoL score represents improvement.

    Time frame: Baseline and at Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 232, and 260

  36. Number of Subjects With Ankylosing Spondylitis Quality of Life Questionaire (ASQoL) MCID Response (MCID <= -1.8 Points) Through Week 260 of Adalimumab Exposure

    ASQoL determined subject's quality of life comprised of 18 questions to be completed by the subject. Each statement on the ASQoL is given a score of "1" or "0." All item scores were summed to give a total score. Total scores ranged from 0 (good quality of life) to 18 (poor quality of life) related to ability to cope, relationships, mood, sleep, motivation, activities of everyday living, independence, and social life. Decrease in ASQoL score represents improvement. Responders are subjects with MCID \<= -1.8 points. MCID was determined by a \>= 1.8 score decrease during exposure to adalimumab.

    Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 232, and 260

  37. Number of Subjects Achieving the Patient Acceptable Symptoms State Through Week 260 of Adalimumab Exposure

    Completed by subject at each visit. The MCIS was a patient reported outcome where the subjects were expected to respond (yes/no) to the following question: Considering all the different ways your disease is affecting you, if you would stay in this state for the next months, do you consider that your current state is satisfactory? An increase in PASS indicates improvement. During earlier weeks of the study PASS was measured/reported as minimal clinically important state (MCIS).

    Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 232, and 260

  38. Mean Change From Baseline in Serum Matrix Metalloproteinase-3 (MMP-3) in Subjects Treated With Any Dose of Adalimumab Through Week 260 of Adalimumab Exposure

    Cartilage and bone degradation were assessed by evaluating changes in MMP-3. A decrease in MMP-3 represents improvement.

    Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260

  39. Mean Change From Baseline in Urine Type II Collagen C Telopeptide (CTX-II) in Subjects Treated With Any Dose of Adalimumab Through Week 260 of Adalimumab Exposure

    Cartilage and bone degradation were assessed by evaluating changes in CTX-II. A decrease in CTX-II represents improvement.

    Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260

  40. Mean Change From Baseline in Serum Type I Collagen N-telopeptide (NTx) in Subjects Treated With Any Dose of Adalimumab Through Week 260 of Adalimumab Exposure

    Cartilage degradation and bone resorption were assessed by evaluating changes in NTx. A decrease in NTx represents improvement.

    Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260

  41. Mean Change in Spinal Spondyloarthritis Research Consortium of Canada (S.P.A.R.C.C.) Magnetic Resonance Imaging (MRI) Index of Disease Activity Score at Weeks 12 and 52 of Adalimumab Exposure

    The S.P.A.R.C.C. MRI index is a tool for scoring inflammation and structural damage in both the spine and sacroiliac (SI) joints. The spinal SPARCC index score consists of 3 subscales (edema, intense edema, and deep edema). Edema was defined as the presence of increased STIR signal in each of 4 Discovertebral unit (DVU) quadrants and was assigned a score (0 = normal signal, 1 = increased signal). The scoring of edema was repeated for each of 3 consecutive sagittal slices with a maximum score of 12 per DVU (range for edema, 0-72). The total spinal SPARCC index score is 0 to 108.

    Time frame: Week 12 and Week 52

  42. Mean Change in Sacroiliac (SI) Spondyloarthritis Research Consortium of Canada (S.P.A.R.C.C.) Magnetic Resonance Imaging (MRI) Index of Disease Activity Score at Weeks 12 and 52 of Adalimumab Exposure

    The S.P.A.R.C.C. MRI index is a tool for scoring inflammation and structural damage in both the spine and sacroiliac (SI) joints. The spinal SPARCC index score consists of 3 subscales (edema, intense edema, and deep edema). Edema was defined as the presence of increased STIR signal in each of 4 Discovertebral unit (DVU) quadrants and was assigned a score (0 = normal signal, 1 = increased signal). The scoring of edema was repeated for each of 3 consecutive sagittal slices with a maximum score of 12 per DVU (range for edema, 0-72). The total spinal SPARCC index score is 0 to 108.

    Time frame: Weeks 12 and 52

07

Results

Posted Apr 28, 2010
Limitations and caveats
The modified SASSS was pooled with a study (NCT00085644) similar in structure and sharing the same endpoints as this study.

Participant flow

The placebo group included subjects who were randomized to placebo even if they received early escape open label adalimumab. The adalimumab exposure group included subjects who were randomized to blinded adalimumab.

Double-Blind
Participant flow — Double-Blind
MilestonePlacebo 40 mg Every Other Week (Eow), Subcutaneous (SC)Any Adalimumab
Started4438
Completed4238
Not completed20
Withdrew: Withdrawal by subject10
Withdrew: Moved10
Open-label
Participant flow — Open-label
MilestonePlacebo 40 mg Every Other Week (Eow), Subcutaneous (SC)Any Adalimumab
Started082
Completed062
Not completed020
Withdrew: Adverse event09
Withdrew: Lack of efficacy02
Withdrew: Pregnancy01
Withdrew: Protocol violation02
Withdrew: Moved01
Withdrew: Withdrawal by subject05

Outcome measures

PrimaryNumber of Subjects With a Reduction in Signs and Symptoms as Measured by Assessments of Ankylosing Spondylitis (ASAS) 20 Response at Week 12

ASAS 20 responders - improvement of \>=20% and absolute improvement of \>=10 units from Baseline in a visual analog scale (VAS) 0 \[no disease activity\]-100 \[high disease activity\]) for \>=3 of 4 domains; Patient's Global Assessment of disease activity VAS; (0\[none\]-100 \[severe\]), Total Back Pain VAS; (0 \[no pain\]-100 \[severe\]), BAth Ankylosing Spondylitis Functional Index (BASFI) VAS (0 \[easy \]-100\[impossible\]); and Inflammation VAS; (1 \[no pain\] to 10 \[severe pain\]) and absence of deterioration in the potential remaining domain. Applied to each scale and not to an overall global scale.

Time frame:
Week 12
Reported as:
Number · participants
Number of Subjects With a Reduction in Signs and Symptoms as Measured by Assessments of Ankylosing Spondylitis (ASAS) 20 Response at Week 12
participantsAdalimumabPlacebo
Responder1812
Non-responder2032
Missing00
Statistical analysis
  • Adalimumab · Chi-squared · p = 0.060 · Odds ratio (or): 20.1 · 95% CI -0.5 to 40.7
SecondaryNumber of Subjects With a Reduction of Signs and Symptoms as Measured in Assessments of Ankylosing Spondylitis (ASAS) 20 - Through Week 260 of Adalimumab Exposure

ASAS 20 responders - improvement of \>=20% and absolute improvement of \>=10 units from Baseline in a visual analog scale (VAS) 0 \[no disease activity\]-100 \[high disease activity\]) for \>=3 of 4 domains; Patient's Global Assessment of disease activity VAS; (0\[none\]-100 \[severe\]), Total Back Pain VAS; (0 \[no pain\]-100 \[severe\]), BASFI VAS (0 \[easy \]-100\[impossible\]); and Inflammation VAS; (1 \[no pain\] to 10 \[severe pain\]) and absence of deterioration in the potential remaining domain. Applied to each scale and not to an overall global scale

Time frame:
Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260
Reported as:
Number · participants
Number of Subjects With a Reduction of Signs and Symptoms as Measured in Assessments of Ankylosing Spondylitis (ASAS) 20 - Through Week 260 of Adalimumab Exposure
participantsAdalimumab
Week 12 Responders (n=82)48
Week 24 Responders (n=80)52
Week 52 Responders (n=78)60
Week 76 Responders (n=75)57
Week 104 Responders (n=74)60
Week 128 Responders (n=70)57
Week 156 Responders (n=69)53
Week 180 Responders (n=62)47
Week 208 Responders (n=67)53
Week 220 Responders (n=64)55
Week 232 Responders (n=62)50
Week 244 Responders (n=54)49
Week 260 Responders (n=27)24
SecondaryNumber of Subjects With a Reduction of Signs and Symptoms as Measured by Assessments in Ankylosing Spondylitis (ASAS) ASAS 50 Through Week 260 of Adalimumab Exposure

ASAS 50 responders - improvement of \>=50% and absolute improvement of \>=20 units (0-100) from Baseline in visual analog scale (VAS) for \>=3 of the 4 domains; Patient's Global Assessment of disease activity; (0\[none\]-100\[severe\]) VAS scale; Total Back Pain VAS; (0 \[no pain\]-100 \[severe\]); BASFI VAS; (0 \[easy \]-100\[impossible\]) and Inflammation VAS; (1 \[no pain\] to 10 \[severe pain\]). In addition, absence of deterioration in the potential remaining domain. Applied to each scale and not overall global scale.

Time frame:
Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260
Reported as:
Number · participants
Number of Subjects With a Reduction of Signs and Symptoms as Measured by Assessments in Ankylosing Spondylitis (ASAS) ASAS 50 Through Week 260 of Adalimumab Exposure
participantsAdalimumab
Week 12 Responders (n=82)29
Week 24 Responders (n=80)38
Week 52 Responders (n=78)45
Week 76 Responders (n=75)46
Week 104 Responders (n=74)47
Week 128 Responders (n=70)46
Week 156 Responders (n=69)42
Week 180 Responders (n=62)38
Week 208 Responders (n=67)37
Week 220 Responders (n=64)42
Week 232 Responders (n=62)42
Week 244 Responders (n=54)40
Week 260 Responders (n=27)24
SecondaryNumber of Subjects With a Reduction of Signs and Symptoms as Measured in Assessments of Ankylosing Spondylitis (ASAS) ASAS 70 Through Week 260 of Adalimumab Exposure

ASAS 70 responders - improvement of \>=70% and absolute improvement of \>=30 units (0-100) from Baseline in visual analog scale (VAS) for \>=3 of the 4 domains; Patient's Global Assessment of disease activity VAS; (0\[none\]-100\[severe\]) Total Back Pain VAS; (0 \[no pain\]-100 \[severe\]); BASFI VAS; (0 \[easy \]-100\[impossible\]) and Inflammation VAS; 1 \[no pain\] to 10 \[severe pain\]). In addition, absence of deterioration in the potential remaining domain. Applied to each scale and not to an overall global scale.

Time frame:
Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260
Reported as:
Number · participants
Number of Subjects With a Reduction of Signs and Symptoms as Measured in Assessments of Ankylosing Spondylitis (ASAS) ASAS 70 Through Week 260 of Adalimumab Exposure
participantsAdalimumab
Week 12 Responders (n=82)18
Week 24 Responders (n=80)27
Week 52 Responders (n=78)32
Week 76 Responders (n=75)34
Week 104 Responders (n=74)35
Week 128 Responders (n=70)32
Week 156 Responders (n=69)31
Week 180 Responders (n=62)24
Week 208 Responders (n=67)28
Week 220 Responders (n=64)26
Week 232 Responders (n=62)28
Week 244 Responders (n=54)29
Week 260 Responders (n=27)14
SecondaryMean Change in Patient's Global Assessment of Disease Activity in Subjects With Adalimumab Exposure Through Week 260

Evaluation of the effect of adalimumab 40 mg every other week (eow) on patient's global assessment of disease activity. The patient was to assess his/her disease activity in the past week using a visual analog scale (VAS) on a scale of 0 to 100 mm with no activity being indicated by 0 and severe activity by 100.

Time frame:
Weeks 12, 24, 36, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260
Reported as:
Mean · mm
Mean Change in Patient's Global Assessment of Disease Activity in Subjects With Adalimumab Exposure Through Week 260
mmAdalimumab
Week 12 (n=82)-28.55 ± 26.808
Week 24 (n=80)-32.43 ± 29.047
Week 52 (n=78)-38.67 ± 26.255
Week 76 (n=75)-40.85 ± 25.934
Week 104 (n=74)-42.72 ± 24.263
Week 128 (n=70)-40.99 ± 27.741
Week 156 (n=69)-40.86 ± 27.203
Week 180 (n=62)-41.74 ± 26.622
Week 208 (n=67)-40.79 ± 26.049
Week 220 (n=64)-43.41 ± 23.854
Week 232 (n=62)-42.77 ± 29.574
Week 244 (n=54)-51.02 ± 23.297
Week 260 (n=27)-51.26 ± 18.451
SecondaryNumber of Subjects With a Reduction of Signs and Symptoms as Measured in Patient's Global Assessment of Disease Activity (an Individual Component of ASAS 20) Through Week 260 of Adalimumab Exposure

The patient assesses his/her disease activity for the past week using a Patient Global Assessment of Disease on visual analog scale (VAS) with 0 being none and 100 being severe.

Time frame:
Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260
Reported as:
Number · participants
Number of Subjects With a Reduction of Signs and Symptoms as Measured in Patient's Global Assessment of Disease Activity (an Individual Component of ASAS 20) Through Week 260 of Adalimumab Exposure
participantsAdalimumab
Week 12 Responder (n=82)53
Week 24 Responder (n=80)56
Week 52 Responder (n=78)61
Week 76 Responder (n=75)59
Week 104 Responder (n=74)64
Week 128 Responder (n=70)57
Week 156 Responder (n=69)57
Week 180 Responder (n=62)52
Week 208 Responder (n=67)56
Week 220 Responder (n=64)57
Week 232 Responder (n=62)53
Week 244 Responder (n=54)50
Week 260 Responder (n=27)26
SecondaryMean Change in the Bath Ankylosing Spondylitis Functional Index (BASFI) in Subjects With Adalimumab Exposure Through Week 260

BASFI consist of a set of 10 questions designed to determine the degree of functional limitation in subjects with AS. The BASFI score was derived based on the average of questions 1 through 10. The first 8 questions considered activities related to functional anatomy and the final 2 questions assessed the subject's ability to cope with everyday life over the last week. A 10 cm visual analog scale (VAS) was used to answer the questions and the mean of the ten scales gave the BASFI score a value between 0 (easy) and 10 (impossible).

Time frame:
Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 232, 244, and 260
Reported as:
Mean · mm
Mean Change in the Bath Ankylosing Spondylitis Functional Index (BASFI) in Subjects With Adalimumab Exposure Through Week 260
mmAdalimumab
Week 12 (n=82)-19.83 ± 23.481
Week 24 (n=80)-24.39 ± 23.559
Week 52 (n=78)-27.83 ± 25.325
Week 76 (n=75)-30.42 ± 24.607
Week 104 (n=74)-30.51 ± 23.382
Week 128 (n=70)-30.67 ± 24.209
Week 156 (n=69)-30.12 ± 24.437
Week 180 (n=62)-28.76 ± 24.060
Week 208 (n=67)-29.81 ± 23.976
Week 220 (n=64)-30.47 ± 23.333
Week 232 (n=62)-31.35 ± 22.964
Week 244 (n=54)-36.65 ± 21.847
Week 260 (n=27)-30.83 ± 22.174
SecondaryBASFI (an Individual Component of ASAS 20) Through Week 260 of Adalimumab Exposure

BASFI consisted of 10 Visual Analog Scale (VAS) questions with a response ranging from 0 (easy) to 100 (impossible). The BASFI score was derived based on the average of questions 1 through 10. A responder is a subject who demonstrates an absolute improvement of at least 10 units and a percentage improvement of at least 20% from Baseline.

Time frame:
Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260
Reported as:
Number · participants
BASFI (an Individual Component of ASAS 20) Through Week 260 of Adalimumab Exposure
participantsAdalimumab
Week 12 Responder (n=82)46
Week 24 Responder (n=80)52
Week 52 Responder (n=78)53
Week 76 Responder (n-75)55
Week 104 Responder (n=74)55
Week 128 Responder (n=70)51
Week 156 Responder (n=69)50
Week 180 Responder (n=62)45
Week 208 Responder (n=67)51
Week 220 Responder (n=64)47
Week 232 Responder (n=62)48
Week 244 Responder (n=54)46
Week 260 Responder (n=27)22
SecondaryMean Change in Total Back Pain Visual Analog Scale (VAS) in Subjects With Adalimumab Exposure Through Week 260

Evaluation of the effect of 40 mg every other week (eow) adalimumab on Total Back Pain VAS. The subject was to assess his/her disease activity in the past week using a total spine VAS on a scale 0 (no pain) to 100 (severe pain).

Time frame:
Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260
Reported as:
Mean · mm
Mean Change in Total Back Pain Visual Analog Scale (VAS) in Subjects With Adalimumab Exposure Through Week 260
mmAdalimumab
Week 12 (n=82)-29.30 ± 26.783
Week 24 (n=80)-31.89 ± 29.675
Week 52 (n=78)-39.46 ± 26.658
Week 76 (n=75)-40.89 ± 26.375
Week 104 (n=74)-43.85 ± 24.730
Week 128 (n=70)-44.07 ± 25.944
Week 156 (n=69)-42.67 ± 27.257
Week 180 (n=62)-41.06 ± 28.604
Week 208 (n=67)-42.16 ± 27.092
Week 220 (n=64)-43.77 ± 25.228
Week 232 (n=62)-42.56 ± 27.844
Week 244 (n=54)-50.30 ± 23.936
Week 260 (n=27)-49.41 ± 27.025
SecondaryTotal Back Pain (an Individual Component of ASAS 20) Through Week 260 of Adalimumab Exposure

A responder is a subject who demonstrates an absolute improvement of at least 10 units and a percentage improvement of at least 20% from Baseline.

Time frame:
Weeks 12, 24, 52, 76, 128, 152, 180, 208, 220, 232, 244, and 260
Reported as:
Number · participants
Total Back Pain (an Individual Component of ASAS 20) Through Week 260 of Adalimumab Exposure
participantsAdalimumab
Week 12 Responder (n=82)56
Week 24 Responder (n=80)57
Week 52 Responder (n=78)66
Week 76 Responder (n=75)62
Week 104 Responder (n=74)64
Week 128 Responder (n=70)62
Week 156 Responder (n=69)59
Week 180 Responder (n=62)50
Week 208 Responder (n=67)56
Week 220 Responder (n=64)59
Week 232 Responder (n=62)52
Week 244 Responder (n=54)53
Week 260 Responder (n=27)25
SecondaryMean Change in Inflammation (Mean of BASDAI Questions 5 and 6) in Subjects With Adalimumab Exposure Through Week 260

The inflammation score is the mean of the two morning stiffness-related BASDAI visual analog scale (VAS) scores (items 5 and 6 of the BASDAI) of 0 (none) to 10 (very severe). A decrease in inflammation represents improvement.

Time frame:
Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260
Reported as:
Mean · cm
Mean Change in Inflammation (Mean of BASDAI Questions 5 and 6) in Subjects With Adalimumab Exposure Through Week 260
cmAdalimumab
Week 12 (n=82)-2.79 ± 2.650
Week 24 (n=80)-3.29 ± 2.882
Week 52 (n=78)-3.89 ± 2.663
Week 76 (n=75)-4.12 ± 2.480
Week 104 (n=74)-4.50 ± 2.465
Week 128 (n=70)-4.32 ± 2.512
Week 156 (n=69)-4.25 ± 2.690
Week 180 (n=62)-4.21 ± 2.522
Week 208 (n=67)-4.22 ± 2.553
Week 220 (n=64)-4.48 ± 2.442
Week 232 (n=62)-4.51 ± 2.786
Week 244 (n=54)-4.96 ± 2.357
Week 260 (n=27)-5.21 ± 2.375
SecondaryInflammation (Individual Component of ASAS 20) (Mean of BASDAI Questions 5 and 6) Through Week 260 of Adalimumab Exposure

A responder is a subject who demonstrates an absolute improvement of at least 10 units and a percentage improvement of at least 20% from Baseline in inflammation (mean of the BASDAI questions 5 and 6 on scale of 0 \[none\] to 10 \[very severe\].

Time frame:
Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260
Reported as:
Number · particpants
Inflammation (Individual Component of ASAS 20) (Mean of BASDAI Questions 5 and 6) Through Week 260 of Adalimumab Exposure
particpantsAdalimumab
Week 12 Responder (n=82)52
Week 24 Responder (n=80)59
Week 52 Responder (n=78)66
Week 76 Responder (n=75)64
Week 104 Responder (n=74)65
Week 128 Responder (n=70)61
Week 156 Responder (n=69)55
Week 180 Responder (n=62)53
Week 208 Responder (n=67)58
Week 220 Responder (n=64)57
Week 232 Responder (n=62)53
Week 244 Responder (n=54)49
Week 260 Responder (n=27)25
SecondaryNumber of Subjects With a Reduction of Signs and Symptoms as Measured in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 20 Through Week 260 of Adalimumab Exposure

The BASDAI is a questionnaire with 6 questions that subject completes by marking answers on a 10-cm Visual Analog Scale (VAS) during the last week with responses that range from 0 (none) to 100(very severe) and measures severity of fatigue, spinal and peripheral joint pain, localized tenderness and morning stiffness. The final BASDAI score ranges from 0 (none) to 10 (very severe). Improvement in BASDAI by 20% was assessed. BASDAI Scoring: 1. Measure each item of the BASDAI in centimeters (out of a total of 10) 2. BASDAI Score = 0.2 (Item 1 + Item 2 + Item 3 + Item 4 + Item 5/2 + Item 6/2).

Time frame:
Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260
Reported as:
Number · Participants
Number of Subjects With a Reduction of Signs and Symptoms as Measured in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 20 Through Week 260 of Adalimumab Exposure
ParticipantsAdalimumab
Week 12 Responders (n=82)61
Week 24 Responders (n=80)61
Week 52 Responders (n=78)64
Week 76 Responders (n=75)64
Week 104 Responders (n=74)65
Week 128 Responders (n=70)60
Week 156 Responders (n=69)59
Week 180 Responders (n=62)55
Week 208 Responders (n=67)61
Week 220 Responders (n=64)58
Week 232 Responders (n=62)57
Week 244 Responders (n=54)51
Week 260 Responders (n=27)26
SecondaryNumber of Subjects With a Reduction of Signs and Symptoms as Measured in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 Through Week 260 of Adalimumab Exposure

The BASDAI is a questionnaire with 6 questions that subject completes by marking answers on a 10-cm Visual Analog Scale (VAS) during the last week with responses that range from 0 (none) to 100 (very severe) and measures severity of fatigue, spinal and peripheral joint pain, localized tenderness and morning stiffness. The final BASDAI score ranges from 0 to 10. Improvement in BASDAI by 50% was assessed. BASDAI Scoring: 1. Measure each item of the BASDAI in centimeters (out of a total of 10) 2. BASDAI Score = 0.2 (Item 1 + Item 2 + Item 3 + Item 4 + Item 5/2 + Item 6/2).

Time frame:
Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260
Reported as:
Number · participants
Number of Subjects With a Reduction of Signs and Symptoms as Measured in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 Through Week 260 of Adalimumab Exposure
participantsAdalimumab
Week 12 Responders (n=82)32
Week 24 Responders (n=80)41
Week 52 Responders (n=78)48
Week 76 Responders (n=75)52
Week 104 Responders (n=74)52
Week 128 Responders (n=70)45
Week 156 Responders (n=69)51
Week 180 Responders (n=62)43
Week 208 Responders (n=67)46
Week 220 Responders (n=64)48
Week 232 Responders (n=62)47
Week 244 Responders (n=54)42
Week 260 Responders (n=27)25
SecondaryNumber of Subjects With a Reduction of Signs and Symptoms as Measured in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 70 Through Week 260 of Adalimumab Exposure

The BASDAI is a questionnaire with 6 questions that subject completes by marking answers on a 10-cm Visual Analog Scale (VAS) during the last week with responses that range from 0 (none) to 100 (very severe) and measures severity of fatigue, spinal and peripheral joint pain, localized tenderness and morning stiffness. The final BASDAI score ranges from 0 to 10. Improvement in BASDAI by 70% was assessed. BASDAI Scoring: 1. Measure each item of the BASDAI in centimeters (out of a total of 10) 2. BASDAI Score = 0.2 (Item 1 + Item 2 + Item 3 + Item 4 + Item 5/2 + Item 6/2).

Time frame:
Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260
Reported as:
Number · participants
Number of Subjects With a Reduction of Signs and Symptoms as Measured in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 70 Through Week 260 of Adalimumab Exposure
participantsAdalimumab
Week 12 Responders (n=82)24
Week 24 Responders (n=80)32
Week 52 Responders (n=78)34
Week 76 Responders (n=75)37
Week 104 Responders (n=74)35
Week 128 Responders (n=70)37
Week 156 Responders (n=69)34
Week 180 Responders (n=62)28
Week 208 Responders (n=67)35
Week 220 Responders (n=64)31
Week 232 Responders (n=62)35
Week 244 Responders (n=54)30
Week 260 Responders (n=27)14
SecondaryMean Change in BASDAI in Subjects With Adalimumab Exposure Through Week 260

The BASDAI is a questionnaire with 6 questions that subject completes by marking answers on a 10-cm Visual Analog Scale (VAS) during the last week with responses that range from 0 (none) to 100 (very severe) and measures severity of fatigue, spinal and peripheral joint pain, localized tenderness and morning stiffness. The final BASDAI score ranges from 0 (none) to 10 (severe). A decrease in BASDAI represents improvement. BASDAI Scoring: 1) Measure each item of the BASDAI in centimeters (out of a total of 10) 2) BASDAI Score = 0.2 (Item 1 + Item 2 + Item 3 + Item 4 + Item 5/2 + Item 6/2).

Time frame:
Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260
Reported as:
Mean · cm
Mean Change in BASDAI in Subjects With Adalimumab Exposure Through Week 260
cmAdalimumab
Week 12 (n=82)-2.48 ± 2.305
Week 24 (n=80)-2.96 ± 2.694
Week 52 (n=78)-3.41 ± 2.511
Week 76 (n=75)-3.70 ± 2.486
Week 104 (n=74)-3.83 ± 2.392
Week 128 (n=70)-3.64 ± 2.536
Week 156 (n=69)-3.63 ± 2.583
Week 180 (n=62)-3.60 ± 2.338
Week 208 (n=67)-3.70 ± 2.367
Week 220 (n=64)-3.83 ± 2.384
Week 232 (n=62)-3.80 ± 2.538
Week 244 (n=54)-4.36 ± 2.214
Week 260 (n=27)-4.48 ± 2.011
SecondaryMean Change in C-Reactive Protein (CRP) (mg/dL) in Subjects With Adalimumab Exposure Through Week 260

Evaluation of the mean changes in CRP in subjects with adalimumab exposure from Baseline through 5 years. The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation via the use of an ultrasensitive assay. A decrease in the level of CRP indicate reduction in inflammation. A decrease in CRP indicates improvement.

Time frame:
Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260
Reported as:
Mean · mg/dL
Mean Change in C-Reactive Protein (CRP) (mg/dL) in Subjects With Adalimumab Exposure Through Week 260
mg/dLAdalimumab
Week 12 (n=82)-1.81 ± 2.782
Week 24 (n=80)-1.81 ± 2.824
Week 52 (n=78)-1.60 ± 3.581
Week 76 (n=75)-1.86 ± 2.897
Week 104 (n=74)-1.90 ± 2.850
Week 128 (n=70)-1.92 ± 3.028
Week 156 (n=69)-1.83 ± 3.060
Week 180 (n=62)-1.99 ± 2.995
Week 208 (n=67)-1.89 ± 3.063
Week 220 (n=64)-2.00 ± 3.117
Week 232 (n=62)-1.67 ± 3.267
Week 244 (n=54)-2.07 ± 3.252
Week 260 (n=27)-1.27 ± 1.513
SecondaryNumber of Subjects With a Disease Controlling Clinical Response From Adalimumab as Measured in Assessments of Ankylosing Spondylitis (ASAS) 40 - Through Week 260 of Adalimumab Exposure

ASAS 40 responder: improvement of \>= 40% and absolute improvement of \>= 20 units (on a scale of 0 to 100) in \>= 3 of the 4 domains: Patient global assessment (VAS score \[0-100 scale\]); Pain (Total Back Pain VAS score 0-100 scale); Function (BASFI score 0-100 scale); Inflammation (the mean of the two morning stiffness-related BASDAI VAS scores (i.e. the average of items 5 and 6 of the BASDAI. Applied to each scale. In addition, absence of deterioration in the potential remaining domain, where deterioration is defined as a net worsening of \> 0 units (on a scale of 0 to 100).

Time frame:
Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244 and 260
Reported as:
Number · participants
Number of Subjects With a Disease Controlling Clinical Response From Adalimumab as Measured in Assessments of Ankylosing Spondylitis (ASAS) 40 - Through Week 260 of Adalimumab Exposure
participantsAdalimumab
Week 12 Responders (n=82)34
Week 24 Responders (n=80)41
Week 52 Responders (n=78)48
Week 76 Responders (n=75)50
Week 104 Responders (n=74)52
Week 128 Responders (n=70)47
Week 156 Responders (n=69)45
Week 180 Responders (n=62)40
Week 208 Responders (n=67)44
Week 220 Responders (n=64)48
Week 232 Responders (n=62)45
Week 244 Responders (n=54)42
Week 260 Responders (n=27)22
SecondaryNumber of Subjects With a Disease Controlling Clinical Response From Adalimumab as Measured in Assessments of Ankylosing Spondylitis Ankylosing Spondylitis (ASAS) 5/6 in Subjects With Adalimumab Exposure Through Week 260

The change in ASAS 5/6 was evaluated for the effect of adalimumab on structural damage. ASAS 5/6 criteria is the 20% improvement in 5 out of 6 domains (physical function \[BASFI\], Total Back Pain, Patient's Global Assessment of Disease Activity, Inflammation \[mean of Questions 5 and 6 of the BASDAI\], spinal mobility \[BASMI\], and acute phase reactants \[CRP\]).

Time frame:
Weeks 12, 16, 20, 24, 30, 36, 42, 48, 52, 64, 76, 88, 104, 116, 128, 140, 156, 168, 180, 192, 208, 220, 232, 244, and 260
Reported as:
Number · participants
Number of Subjects With a Disease Controlling Clinical Response From Adalimumab as Measured in Assessments of Ankylosing Spondylitis Ankylosing Spondylitis (ASAS) 5/6 in Subjects With Adalimumab Exposure Through Week 260
participantsAdalimumab
Week 12 Responders (n=82)45
Week 24 Responders (n=80)49
Week 52 Responders (n=78)55
Week 76 Responders (n=75)57
Week 104 Responders (n=74)56
Week 128 Responders (n=70)53
Week 156 Responders (n=69)51
Week 180 Responders (n=62)45
Week 208 Responders (n=67)48
Week 220 Responders (n=64)47
Week 232 Responders (n=62)49
Week 244 Responders (n=54)42
Week 260 Responders (n=27)22
SecondaryNumber of Subjects With a Disease Controlling Clinical Response From Adalimumab as Measured in Partial Remission Response in Subjects With Adalimumab Exposure Through Week 260

Evaluation of the mean changes in BASDAI in subjects with adalimumab exposure from Baseline through 5 years for the effect of adalimumab on structural damage. Partial remission was calculated as follows: A value below 20 on a 0 - 100-point scale in each of the four domains of the ASAS (Patient's Global Assessment of Disease Activity, Pain, Function and Inflammation). Partial remission is also regarded as a low disease activity state.

Time frame:
Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260
Reported as:
Number · participants
Number of Subjects With a Disease Controlling Clinical Response From Adalimumab as Measured in Partial Remission Response in Subjects With Adalimumab Exposure Through Week 260
participantsAdalimumab
Week 12 Responders (n=82)23
Week 24 Responders (n=80)25
Week 52 Responders (n=78)31
Week 76 Responders (n=75)33
Week 104 Responders (n=74)35
Week 128 Responders (n=70)31
Week 156 Responders (n=69)28
Week 180 Responders (n=62)29
Week 208 Responders (n=67)32
Week 220 Responders (n=64)29
Week 232 Responders (n=62)34
Week 244 Responders (n=54)25
Week 260 Responders (n=27)16
SecondaryMean Change in the Bath Ankylosing Spondylitis Metrology Index (BASMI) in Subjects With Adalimumab Exposure Through Week 260

BASMI measures the range of motion based on five clinical measurements: 1) cervical rotation, 2) tragus to wall distance, 3) lumbar side flexion, 4) lumbar flexion (modified Schober's) and 5) intermalleolar distance. BASMI 0 = indicates mild disease involvement, 1 = moderate disease, and 2 = severe disease involvement. The results for cervical rotation and lumbar side flexion are the means of the left and right measurements. Scoring range 0-10. The higher the BASMI score, the more severe was the subject's limitation of movement due to their AS.

Time frame:
Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260
Reported as:
Mean · cm
Mean Change in the Bath Ankylosing Spondylitis Metrology Index (BASMI) in Subjects With Adalimumab Exposure Through Week 260
cmAdalimumab
Week 12 (n=82)-0.42 ± 1.124
Week 24 (n=80)-0.50 ± 1.146
Week 52 (n=78)-0.61 ± 1.492
Week 76 (n=75)-0.64 ± 1.321
Week 104 (n=74)-0.78 ± 1.550
Week 128 (n=69)-1.01 ± 1.477
Week (156 (n=69)-1.00 ± 1.426
Week 180 (n=62)-1.03 ± 1.746
Week 208 (n=67)-1.04 ± 1.628
Week 220 (n=64)-0.86 ± 1.521
Week 232 (n=60)-0.88 ± 1.541
Week 244 (n=51)-1.00 ± 1.659
Week 260 (n=27)-0.70 ± 1.325
SecondaryMean Change in Edmonton Ankylosing Spondylitis Metrology Index (EDASMI) in Subjects With Adalimumab Exposure Through Week 260

The EDASMI is a composite spinal mobility index comprised of 4 measures: 1) cervical rotation, 2) lumbar side flexion, 3) chest expansion, and 4) hip internal rotation spread. A grade of 0-4 scoring system was developed for each of the measures. The sum of 4 items (range 0 to 16) provide the EDASMI score. Decrease in EDASMI represents improvement. All EDASMI measures were done with a simple tape measure and recorded in centimeters (cm) by a rheumatologist and a clinician nurse.

Time frame:
Weeks 12, 24, 52, 104, 128, 156, 180, 208, 220, 232, 244, and 260
Reported as:
Mean · cm
Mean Change in Edmonton Ankylosing Spondylitis Metrology Index (EDASMI) in Subjects With Adalimumab Exposure Through Week 260
cmAdalimumab
Week 12 (n=82)-1.11 ± 1.990
Week 24 (n=80)-1.16 ± 2.143
Week 52 (n=78)-1.47 ± 2.408
Week 104 (n=75)-1.24 ± 2.357
Week 128 (n=69)-1.59 ± 3.124
Week 156 (n=69)-1.50 ± 3.457
Week 180 (n=62)-1.76 ± 3.227
Week 208 (n=67)-1.41 ± 3.705
Week 220 (n=64)-1.34 ± 3.301
Week 232 (n=60)-1.65 ± 3.267
Week 244 (n=51)-1.42 ± 3.199
Week 260 (n=27)-1.56 ± 3.566
SecondaryMean Change in Chest Expansion (CE) in Subjects With Adalimumab Exposure Through Week 260

The patient is in a sitting position on the examination table with the hands on the hips. A pen mark is made at the xiphisternum and a tape measure placed around the circumference of the patient's chest at this level. The patient is asked to take a deep breath and to exhale as completely as possible while looking directly ahead. The measurement (in cm) is noted. The patient is asked to inhale as deeply as possible and the measurement (in cm) is noted. The difference in the 2 measurement points (in cm) constitutes the value for CE. An increase in chest expansion represents improvement

Time frame:
Weeks 12, 24, 52,104, 128, 156, 180, 208, 220, 232, 244, and 260
Reported as:
Mean · cm
Mean Change in Chest Expansion (CE) in Subjects With Adalimumab Exposure Through Week 260
cmAdalimumab
Week 12 (n=82)0.47 ± 1.907
Week 24 (n=80)0.66 ± 1.717
Week 52 (n=78)0.66 ± 1.803
Week 104 (n=75)0.51 ± 1.875
Week 128 (n=69)0.60 ± 2.287
Week 156 (n=69)0.49 ± 1.881
Week 180 (n=62)0.57 ± 1.960
Week 208 (n=67)0.60 ± 2.252
Week 220 (n=64)0.46 ± 2.013
Week 232 (n=60)0.44 ± 2.082
Week 244 (n=51)0.39 ± 2.074
Week 260 (n=27)0.52 ± 2.112
SecondaryMean Change in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) in Subjects With Adalimumab Exposure Through Week 260

MASES is measured by scoring of entheses of 0 (no tenderness) to 3 (severe tenderness) at 13 sites on the body. The score was derived as the sum of the 13 scores divided by 3 and the total range is 0 (no tenderness) to 13 (severe tenderness).

Time frame:
Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 232, and 260
Reported as:
Mean · Units on a scale
Mean Change in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) in Subjects With Adalimumab Exposure Through Week 260
Units on a scaleAdalimumab
Week 12 (n=82)-2.26 ± 5.335
Week 24 (n=80)-3.26 ± 4.608
Week 52 (n=77)-3.61 ± 5.573
Week 76 (n=59)-3.56 ± 5.392
Week 104 (n=74)-3.66 ± 5.253
Week 128 (n=52)-3.52 ± 5.207
Week 156 (n=67)-3.27 ± 5.224
Week 180 (n=50)-3.72 ± 4.887
Week 208 (n=66)-4.11 ± 5.114
Week 232 (n=48)-3.81 ± 5.640
Week 260 (n=49)-5.47 ± 5.393
SecondaryMean Change in the Bath Ankylosing Spondylitis Global Index (BAS-G) in Subjects With Adalimumab Exposure Through Week 260

BAS-G consisted of two questions that asked the subject to indicate, on a 10 cm VAS, the effect the disease had on their well being over 1) last week, and 2) last 6 months. BAS-G was measured by two VAS scores (0 to 100 mm) to reflect the effect of Ankylosing Spondylitis on subject's well-being over the past week and over the last 6 months, respectively. The average of these two scores was reported. The mean of the two scores give a BAS-G score of 0-10.

Time frame:
Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260
Reported as:
Mean · mm
Mean Change in the Bath Ankylosing Spondylitis Global Index (BAS-G) in Subjects With Adalimumab Exposure Through Week 260
mmAdalimumab
Week 12 (n=82)-23.41 ± 20.456
Week 24 (n=80)-32.78 ± 23.638
Week 52 (n=78)-39.40 ± 23.975
Week 76 (n=75)-42.63 ± 23.133
Week 104 (n=74)-44.78 ± 22.845
Week 128 (n=70)-43.28 ± 25.578
Week 156 (n=69)-44.30 ± 23.826
Week 180 (n=62)-45.05 ± 22.934
Week 208 (n=67)-45.08 ± 22.681
Week 220 (n=64)-46.73 ± 21.367
Week 232 (n=62)-45.56 ± 23.453
Week 244 (n=54)-53.69 ± 18.349
Week 260 (n=27)-50.93 ± 18.478
SecondaryMean Change in Swollen Joint Count for 44 Joints (44 SJC) in Subjects With Adalimumab Exposure Through Week 260

Change from Baseline in the swollen joint index. An assessment of 44 joints for SJC done by physical examination. Joint swelling was classified as present ("1"), absent ("0") or injected/replaced ("9"). The joints assessed were: Sternoclavicular, Acromioclavicular, Shoulder, Elbow, Wrist, Metacarpophalangeal (1-5), Thumb interphalangeal, Proximal interphalangeal (2-5, Knee, Ankle, and Metatarsophalangeal (1-5).

Time frame:
Weeks 12, 24, 36, 52, 76, 104, 128, 156, 180, 208, 232, and 260
Reported as:
Mean · score on scale
Mean Change in Swollen Joint Count for 44 Joints (44 SJC) in Subjects With Adalimumab Exposure Through Week 260
score on scaleAdalimumab
Week 12 (n=82)-0.29 ± 4.171
Week 24 (n=80)-1.00 ± 4.792
Week 52 (n=78)-1.45 ± 4.497
Week 76 (n=59)-0.92 ± 4.427
Week 104 (n=51)-0.81 ± 5.789
Week 128 (n=70)-0.04 ± 2.592
Week 156 (n=68)-1.26 ± 5.231
Week 180 (n=50)-1.38 ± 4.453
Week 208 (n=66)-1.29 ± 5.737
Week 232 (n=48)-0.33 ± 2.300
Week 260 (n=49)-2.37 ± 5.619
SecondaryMean Change From Baseline in the Tender Joint Count for 46 Joints (TJC 46) in Subjects With Adalimumab Exposure Through Week 260 of Adalimumab Exposure

Assessment of 46 joints for TJC was done by physical examination. Joint tenderness was classified as present ("1"), absent ("0") or injected/replaced ("9"). The joints assessed were: Sternoclavicular, Acromioclavicular, Shoulder, Elbow, Wrist, Metacarpophalangeal (1-5), Thumb interphalangeal, Proximal interphalangeal (2-5, Knee, Ankle, and Metatarsophalangeal (1-5).

Time frame:
Weeks 12, 24, 36, 52, 76, 104, 128, 156, 180, 208, 232, and 260
Reported as:
Mean · score on scale
Mean Change From Baseline in the Tender Joint Count for 46 Joints (TJC 46) in Subjects With Adalimumab Exposure Through Week 260 of Adalimumab Exposure
score on scaleAdalimumab
Week 12 (n=82)-1.66 ± 6.639
Week 24 (n=80)-2.36 ± 6.582
Week 52 (n=78)-3.63 ± 5.920
Week 76 (n=59)-3.34 ± 7.184
Week 104 (n=74)-2.78 ± 7.731
Week 128 (n=52)-3.10 ± 6.307
Week 156 (n=68)-2.69 ± 8.086
Week 180 (n=50)-2.90 ± 7.833
Week 208 (n=66)-3.48 ± 7.341
Week 232 (n=48)-3.23 ± 7.197
Week 260 (n=49)-5.84 ± 7.290
SecondaryMean Change in Physician's Global Assessment of Disease Activity in Subjects With Adalimumab Exposure Through Week 260

The physician will globally assess the subject's current disease state using a VAS scale with 0 being very good and 100 being very bad.

Time frame:
Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260
Reported as:
Mean · mm
Mean Change in Physician's Global Assessment of Disease Activity in Subjects With Adalimumab Exposure Through Week 260
mmAdalimumab
Week 12 (n=82)-24.80 ± 24.892
Week 24 (n=80)-33.46 ± 28.197
Week 52 (n=78)-38.68 ± 24.745
Week 76 (n=75)-38.21 ± 24.570
Week 104 (n=74)-41.96 ± 23.205
Week 128 (n=70)-42.26 ± 23.083
Week 156 (n=69)-38.75 ± 25.728
Week 180 (n=62)-42.84 ± 25.870
Week 208 (n=66)-41.27 ± 26.348
Week 220 (n=63)-43.92 ± 22.369
Week 232 (n=58)-43.60 ± 23.357
Week 244 (n=50)-52.98 ± 16.340
Week 260 (n=27)-50.33 ± 19.958
SecondaryMean Change in Nocturnal Pain in Subjects With Adalimumab Exposure Through Week 260

The subject was to assess his/her nocturnal pain intensity for the past week using a Nocturnal Pain Visual Analog Scale (Nocturnal Pain VAS). The range was 0 to 100 mm with no pain being indicated by 0 and worse possible pain by 100.

Time frame:
Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260
Reported as:
Mean · mm
Mean Change in Nocturnal Pain in Subjects With Adalimumab Exposure Through Week 260
mmAdalimumab
Week 12 (n=82)-25.49 ± 29.566
Week 24 (n=80)-28.08 ± 31.414
Week 52 (n=78)-33.88 ± 30.432
Week 76 (n=75)-34.87 ± 29.715
Week 104 (n=74)-37.07 ± 28.661
Week 128 (n=70)-36.77 ± 29.030
Week 156 (n=69)-34.91 ± 30.125
Week 180 (n=62)-33.50 ± 30.180
Week 208 (n=67)-34.00 ± 29.757
Week 220 (n=64)-35.33 ± 28.620
Week 232 (n=62)-34.11 ± 30.186
Week 244 (n=54)-40.61 ± 26.873
Week 260 (n=27)-33.41 ± 30.147
SecondaryMean Change in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale in Subjects With Adalimumab Exposure Through Week 260

The FACIT-Fatigue scale: overall score of 13 general questions divided into four primary Quality of Life (QoL) domains: 1) Physical Well-Being, 2) Social/Family Well-Being, 3) Emotional Well-Being, and 4) Functional Well-Being. For each question subject rates his/her condition for the past week on a 5-point scale ranging from 0 (not at all) to 4 (very much). The score ranges from 0 (highest level of fatigue) to 52 with 52 being the lowest level of fatigue.

Time frame:
Baseline and at Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 232, and 260
Reported as:
Mean · unit on a scale
Mean Change in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale in Subjects With Adalimumab Exposure Through Week 260
unit on a scaleAdalimumab
Week 12 (n=74)9.49 ± 9.994
Week 24 (n=53)9.03 ± 11.225
Week 52 (n=78)11.48 ± 10.331
Week 76 (n=59)11.61 ± 11.171
Week 104 (n=74)12.46 ± 10.520
Week 128 (n=52)11.08 ± 11.396
Week 156 (n=68)11.62 ± 11.391
Week 180 (n=50)10.56 ± 10.011
Week 280 (n=66)11.60 ± 10.761
Week 232 (n=48)10.13 ± 11.112
Week 260 (n=49)16.17 ± 9.276
SecondaryMean Change in the SF-36 Health Survey Index Physical Component Summary [PCS] Through Week 260 of Adalimumab Exposure

Change from Baseline in the SF-36 Health Survey Index completed by Subject to help subject keep track of how he/she was feeling and how well he/she was able to do usual activities. Components of the SF-36 included the PCS and MCS, respectively. An increase in SF-36 PCS or MCS indicate improvement.

Time frame:
Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 232, and 260
Reported as:
Mean · score on scale
Mean Change in the SF-36 Health Survey Index Physical Component Summary [PCS] Through Week 260 of Adalimumab Exposure
score on scaleAdalimumab
Week 12 (n=74)7.60 ± 8.320
Week 24 (n=53)9.26 ± 9.389
Week 52 (n=78)10.63 ± 8.982
Week 76 (n=59)11.26 ± 8.685
Week 104 (n=74)11.29 ± 9.668
Week 128 (n=50)11.76 ± 8.868
Week 156 (n=68)11.73 ± 9.726
Week 180 (n=48)10.74 ± 10.781
Week 208 (n=60)12.42 ± 9.925
Week 232 (n=21)10.88 ± 10.401
Week 260 (n=5)12.19 ± 8.410
SecondaryNumber of Subjects With SF-36 Physical Component Summary (PCS) of Minimal Clinically Important Difference (MCID) Response Through Week 260 of Adalimumab Exposure

SF-36 is a standardized survey evaluating 8 aspects of functional health and well being; physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, and mental health. The score for a section is an average of the individual question scores, which are scaled 0(no functioning)to 100 (highest level of functioning). Responders were subjects with MCID \> 3 points. Minimal clinically important difference (MCID) for PCS was determined by a \>= 3.0 point increase during exposure to adalimumab.

Time frame:
Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 232, and 260
Reported as:
Number · participants
Number of Subjects With SF-36 Physical Component Summary (PCS) of Minimal Clinically Important Difference (MCID) Response Through Week 260 of Adalimumab Exposure
participantsAdalimumab
Week 12 Responders (n=74)51
Week 24 Responders (n=53)41
Week 52 Responders (n=78)65
Week 76 Responders (n=59)50
Week 104 Responders (n=74)61
Week 128 Responders (n=50)43
Week 156 Responders (n=68)56
Week 180 Responders (n=48)38
Week 208 Responders (n=60)49
Week 232 Responders (n=21)15
Week 260 Responders (n=5)4
SecondaryMean Change in the SF-36 Health Survey Index Mental Component Summary [MCS] Through Week 260 of Adalimumab Exposure

SF-36 is a standardized survey evaluating 8 aspects of functional health and well being; physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, and mental health. The score for a section is an average of the individual question scores, which are scaled 0 (no functioning) to 100 (highest level of functioning). Change from Baseline in the SF-36 Health Survey Index was completed by Subject. Components of the SF-36 included the PCS and MCS, respectively. An increase in SF-36 PCS or MCS indicated improvement.

Time frame:
Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 232, and 260
Reported as:
Mean · score on scale
Mean Change in the SF-36 Health Survey Index Mental Component Summary [MCS] Through Week 260 of Adalimumab Exposure
score on scaleAdalimumab
Week 12 (n=74)6.91 ± 9.109
Week 24 (n=53)3.88 ± 10.617
Week 52 (n=78)6.14 ± 10.466
Week 76 (n=59)7.00 ± 9.469
Week 104 (n=74)6.45 ± 10.821
Week 128 (n=50)4.89 ± 11.234
Week 156 (n=68)5.76 ± 10.687
Week 180 (n=48)5.30 ± 11.434
Week 208 (n=60)6.85 ± 10.366
Week 232 (n=21)9.00 ± 11.213
Week 260 (n=5)9.40 ± 13.224
SecondaryNumber of Subjects With SF-36 Mental Component Summary (MCS) of Minimal Clinically Important Difference (MCID) Response Through Week 260 of Adalimumab Exposure

SF-36 is a standardized survey completed by Subject, evaluating 8 aspects of functional health and well being; physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, and mental health. The score for a section is an average of the individual question scores, which are scaled 0 (no functioning) to 100 (highest level of functioning). Responders are subjects with MCID \> 3 points. Minimal clinically important difference (MCID) for PCS was determined by a \>= 3.0 point increase during exposure to adalimumab.

Time frame:
Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 232, and 260
Reported as:
Number · participants
Number of Subjects With SF-36 Mental Component Summary (MCS) of Minimal Clinically Important Difference (MCID) Response Through Week 260 of Adalimumab Exposure
participantsAdalimumab
Week 12 Responders (n=74)49
Week 24 Responders (n=53)29
Week 52 Responders (n=78)50
Week 76 Responders (n=59)39
Week 104 Responders (n=74)46
Week 128 Responders (n=50)30
Week 156 Responders (n=68)42
Week 180 Responders (n=48)27
Week 208 Responders (n=60)41
Week 232 Responders (n=21)16
Week 260 Responders (n=5)4
SecondaryMean Change in Health Utilities Index-3 (HUI-3) Through Week 260 of Adalimumab Exposure

Change from baseline in Health Utility Index Mark 3 (HUI-3) was reported. The HUI-3 is a generic approach to the measurement of health status and assessment of HRQL. The HUI-3 was comprised of two complementary components. The first component was a multi-attribute health status classification system that was used to describe health status. The second component was a multi-attribute utility function that was used to value health status as measured within the corresponding multi-attribute health status classification system. An increase in the HUI-3 score represents improvement.

Time frame:
Weeks 24, 52, 104, 128, 156, 180, 208, 232, and 260
Reported as:
Mean · score on scale
Mean Change in Health Utilities Index-3 (HUI-3) Through Week 260 of Adalimumab Exposure
score on scaleAdalimumab
Week 24 (n=81)0.17 ± 0.234
Week 52 (n=62)0.21 ± 0.223
Week 104 (n=74)0.19 ± 0.245
Week 128 (n=47)0.19 ± 0.271
Week 156 (n=62)0.24 ± 0.254
Week 180 (n=49)0.23 ± 0.259
Week 208 (n=65)0.24 ± 0.257
Week 232 (n=47)0.18 ± 0.306
Week 260 (n=48)0.27 ± 0.249
SecondaryMean Change in the Ankylosing Spondylitis Quality of Life Questionaire (ASQoL) in Subjects Through Week 260 of Adalimumab Exposure

ASQoL determined subject's quality of life and is comprised of 18 questions (yes or no) to be completed by the subject. Each statement on the ASQoL is given a score of "1" or "0." All item scores were summed to give a total score or index. Total scores ranged from 0 (good quality of life) to 18 (poor quality of life) related to ability to cope, relationships, mood, sleep, motivation, activities of everyday living, independence, and social life. Decrease in ASQoL score represents improvement.

Time frame:
Baseline and at Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 232, and 260
Reported as:
Mean · score on a scale
Mean Change in the Ankylosing Spondylitis Quality of Life Questionaire (ASQoL) in Subjects Through Week 260 of Adalimumab Exposure
score on a scaleAdalimumab
Week 12 (n=74)-3.90 ± 4.556
Week 24 (n=53)-3.80 ± 4.993
Week 52 (n=78)-5.40 ± 4.724
Week 76 (n=59)-5.47 ± 4.830
Week 104 (n=74)-5.55 ± 4.593
Week 128 (n=52)-5.46 ± 4.741
Week 156 (n=68)-5.51 ± 5.015
Week 180 (n=50)-4.95 ± 5.415
Week 208 (n=66)-5.80 ± 5.127
Week 232 (n=48)-5.35 ± 5.538
Week 160 (n=49)-7.46 ± 4.811
SecondaryNumber of Subjects With Ankylosing Spondylitis Quality of Life Questionaire (ASQoL) MCID Response (MCID <= -1.8 Points) Through Week 260 of Adalimumab Exposure

ASQoL determined subject's quality of life comprised of 18 questions to be completed by the subject. Each statement on the ASQoL is given a score of "1" or "0." All item scores were summed to give a total score. Total scores ranged from 0 (good quality of life) to 18 (poor quality of life) related to ability to cope, relationships, mood, sleep, motivation, activities of everyday living, independence, and social life. Decrease in ASQoL score represents improvement. Responders are subjects with MCID \<= -1.8 points. MCID was determined by a \>= 1.8 score decrease during exposure to adalimumab.

Time frame:
Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 232, and 260
Reported as:
Number · participants
Number of Subjects With Ankylosing Spondylitis Quality of Life Questionaire (ASQoL) MCID Response (MCID <= -1.8 Points) Through Week 260 of Adalimumab Exposure
participantsAdalimumab
Week 12 Responders (n=74)48
Week 24 Responders (n=53)27
Week 52 Responders (n=78)60
Week 76 Responders (n=59)42
Week 104 Responders (n=74)59
Week 128 Responders (n=52)41
Week 156 Responders (n=68)50
Week 180 Responders (n=50)37
Week 208 Responders (n=66)51
Week 232 Responders (n=48)36
Week 260 Responders (n=49)43
SecondaryNumber of Subjects Achieving the Patient Acceptable Symptoms State Through Week 260 of Adalimumab Exposure

Completed by subject at each visit. The MCIS was a patient reported outcome where the subjects were expected to respond (yes/no) to the following question: Considering all the different ways your disease is affecting you, if you would stay in this state for the next months, do you consider that your current state is satisfactory? An increase in PASS indicates improvement. During earlier weeks of the study PASS was measured/reported as minimal clinically important state (MCIS).

Time frame:
Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 232, and 260
Reported as:
Number · participants
Number of Subjects Achieving the Patient Acceptable Symptoms State Through Week 260 of Adalimumab Exposure
participantsAdalimumab
Week 12 Responders (n=82)35
Week 24 Responders (n=80)44
Week 52 Responders (n=78)50
Week 76 Responders (n=75)50
Week 104 Responders (n=71)49
Week 128 Responders (n=51)35
Week 156 Responders (n=68)48
Week 180 Responders (n=48)32
Week 208 Responders (n=64)42
Week 232 Responders (n=47)34
Week 260 Responders (n=46)37
SecondaryMean Change From Baseline in Serum Matrix Metalloproteinase-3 (MMP-3) in Subjects Treated With Any Dose of Adalimumab Through Week 260 of Adalimumab Exposure

Cartilage and bone degradation were assessed by evaluating changes in MMP-3. A decrease in MMP-3 represents improvement.

Time frame:
Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260
Reported as:
Mean · ng/mL
Mean Change From Baseline in Serum Matrix Metalloproteinase-3 (MMP-3) in Subjects Treated With Any Dose of Adalimumab Through Week 260 of Adalimumab Exposure
ng/mLAdalimumab
Week 12 (n=73)-29.06 ± 98.960
Week 24 (n=52)-6.31 ± 20.115
Week 52 (n=78)-24.89 ± 97.671
Week 76 (n=60)-24.64 ± 102.536
Week 104 (n=74)-23.05 ± 94.471
Week 128 (n=51)-7.37 ± 21.704
Week 156 (n=66)-33.71 ± 115.252
Week 180 (n=50)-12.56 ± 36.045
Week 208 (n=62)-31.37 ± 115.467
Week 220 (n=26)-67.52 ± 169.992
Week 232 (n=36)-9.88 ± 24.293
Week 244 (n=27)-67.88 ± 168.991
Week 260 (n=27)-11.60 ± 25.776
SecondaryMean Change From Baseline in Urine Type II Collagen C Telopeptide (CTX-II) in Subjects Treated With Any Dose of Adalimumab Through Week 260 of Adalimumab Exposure

Cartilage and bone degradation were assessed by evaluating changes in CTX-II. A decrease in CTX-II represents improvement.

Time frame:
Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260
Reported as:
Mean · ng/mmolcr
Mean Change From Baseline in Urine Type II Collagen C Telopeptide (CTX-II) in Subjects Treated With Any Dose of Adalimumab Through Week 260 of Adalimumab Exposure
ng/mmolcrAdalimumab
Week 12 (n=74)-72.27 ± 201.493
Week 24 (n=52)-39.87 ± 173.995
Week 52 (n=75)-51.56 ± 288.316
Week 76 (n=58)-89.93 ± 324.185
Week 104 (n=73)-65.04 ± 286.539
Week 128 (n=51)-96.53 ± 293.026
Week 156 (n=64)-125.92 ± 332.340
Week 180 (n=45)-168.02 ± 368.086
Week 208 (n=55)-172.18 ± 350.006
Week 220 (n=26)-175.42 ± 387.357
Week 232 (n=35)-113.54 ± 354.684
Week 244 (n=26)-150.15 ± 383.965
Week 260 (n=24)-141.42 ± 411.224
SecondaryMean Change From Baseline in Serum Type I Collagen N-telopeptide (NTx) in Subjects Treated With Any Dose of Adalimumab Through Week 260 of Adalimumab Exposure

Cartilage degradation and bone resorption were assessed by evaluating changes in NTx. A decrease in NTx represents improvement.

Time frame:
Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260
Reported as:
Mean · NM BCE
Mean Change From Baseline in Serum Type I Collagen N-telopeptide (NTx) in Subjects Treated With Any Dose of Adalimumab Through Week 260 of Adalimumab Exposure
NM BCEAdalimumab
Week 12 (n=73)0.63 ± 3.890
Week 24 (n=53)0.33 ± 3.857
Week 52 (n=78)-1.02 ± 4.539
Week 76 (n=60)-0.05 ± 5.735
Week 104 (n=74)-0.17 ± 3.891
Week 128 (n=50)-1.00 ± 4.414
Week 156 (n=66)-0.82 ± 3.749
Week 180 (n=50)0.52 ± 9.020
Week 208 (n=62)-1.94 ± 4.182
Week 220 (n=26)-3.10 ± 4.097
Week 232 (n=36)-1.47 ± 3.020
Week 244 (n=27)-4.59 ± 4.977
Week 260 (n=27)-2.89 ± 2.903
SecondaryMean Change in Spinal Spondyloarthritis Research Consortium of Canada (S.P.A.R.C.C.) Magnetic Resonance Imaging (MRI) Index of Disease Activity Score at Weeks 12 and 52 of Adalimumab Exposure

The S.P.A.R.C.C. MRI index is a tool for scoring inflammation and structural damage in both the spine and sacroiliac (SI) joints. The spinal SPARCC index score consists of 3 subscales (edema, intense edema, and deep edema). Edema was defined as the presence of increased STIR signal in each of 4 Discovertebral unit (DVU) quadrants and was assigned a score (0 = normal signal, 1 = increased signal). The scoring of edema was repeated for each of 3 consecutive sagittal slices with a maximum score of 12 per DVU (range for edema, 0-72). The total spinal SPARCC index score is 0 to 108.

Time frame:
Week 12 and Week 52
Reported as:
Mean · score on a scale
Mean Change in Spinal Spondyloarthritis Research Consortium of Canada (S.P.A.R.C.C.) Magnetic Resonance Imaging (MRI) Index of Disease Activity Score at Weeks 12 and 52 of Adalimumab Exposure
score on a scaleAdalimumabPlacebo
Week 12-9.9 ± 1.01-0.8 ± 0.94
Week 52-11.2 ± 1.08-13.7 ± 1.03
SecondaryMean Change in Sacroiliac (SI) Spondyloarthritis Research Consortium of Canada (S.P.A.R.C.C.) Magnetic Resonance Imaging (MRI) Index of Disease Activity Score at Weeks 12 and 52 of Adalimumab Exposure

The S.P.A.R.C.C. MRI index is a tool for scoring inflammation and structural damage in both the spine and sacroiliac (SI) joints. The spinal SPARCC index score consists of 3 subscales (edema, intense edema, and deep edema). Edema was defined as the presence of increased STIR signal in each of 4 Discovertebral unit (DVU) quadrants and was assigned a score (0 = normal signal, 1 = increased signal). The scoring of edema was repeated for each of 3 consecutive sagittal slices with a maximum score of 12 per DVU (range for edema, 0-72). The total spinal SPARCC index score is 0 to 108.

Time frame:
Weeks 12 and 52
Reported as:
Mean · score on a scale
Mean Change in Sacroiliac (SI) Spondyloarthritis Research Consortium of Canada (S.P.A.R.C.C.) Magnetic Resonance Imaging (MRI) Index of Disease Activity Score at Weeks 12 and 52 of Adalimumab Exposure
score on a scaleAdalimumab ExposurePlacebo
Week 12-4.1 ± 0.64-0.8 ± 0.60
Week 52-5.4 ± 0.34-5.5 ± 0.32
PrimaryMean Change in the Modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) Compared Against a Historical Control Group (Outcomes in Ankylosing Spondylitis International Study [OASIS]) Using the ANCOVA Model Adjusting for Baseline mSASSS Score

Radiographic progression was based on change in mSASSS scoring (comparison of the means) from double-blind Baseline visit to Week 104. The mSASSS is the sum of the lumbar and cervical spine score ( 0 \[no change\] to 72 \[progression\]), derived from scoring the anterior site of the lumbar spine (T12 to S1) and the cervical spine (C2 to T1) as either 0 (normal), 1 (erosion, sclerosis, or squaring), 2 (syndesmophyte), 3 (bridging syndesmophyte), or N (vertebral body not evaluable). Data from NCT00195819 was compared with data from AS patients in OASIS.

Time frame:
Baseline and Week 104
Reported as:
Mean · score on a scale
Mean Change in the Modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) Compared Against a Historical Control Group (Outcomes in Ankylosing Spondylitis International Study [OASIS]) Using the ANCOVA Model Adjusting for Baseline mSASSS Score
score on a scaleAny Adalimumab
Adalimumab in M03-606 (N=70)0.5 ± 0.36
OASIS (N=169)0.9 ± 0.23
Statistical analysis
  • Any Adalimumab · ANCOVA · p = 0.387 · Mean difference (net): -0.4

Adverse events

Collected over Adverse event data were collected through Week 260 of adalimumab exposure.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adalimumab—20/82 (24.4%)78/82 (95.1%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventAdalimumab
Diverticular perforationGastrointestinal disorders2/82
OsteoarthritisMusculoskeletal and connective tissue disorders2/82
DiplopiaEye disorders1/82
PeritonitisGastrointestinal disorders1/82
Umbilical herniaGastrointestinal disorders1/82
AppendicitisInfections and infestations1/82
Escherichia sepsisInfections and infestations1/82
GastroenteritisInfections and infestations1/82
PneumoniaInfections and infestations1/82
PyelonephritisInfections and infestations1/82
Most frequent other events
Showing 10 of 40
Most frequent other events
EventAdalimumab
NasopharyngitisInfections and infestations38/82
Upper Respiratory Tract InfectionInfections and infestations33/82
Ankylosing SpondylitisMusculoskeletal and connective tissue disorders20/82
HeadacheNervous system disorders20/82
InfluenzaInfections and infestations14/82
FatigueGeneral disorders13/82
ArthralgiaMusculoskeletal and connective tissue disorders12/82
Back PainMusculoskeletal and connective tissue disorders11/82
NauseaGastrointestinal disorders10/82
Pain in ExtremityMusculoskeletal and connective tissue disorders10/82

Baseline characteristics

Age Continuous
Age Continuous(participants)Adalimumab
<=40 years35
Between 40 and 65 years45
>=65 years2
Age Continuous
Age Continuous(years)Adalimumab
Mean40.9 ± 10.97
Sex: Female, Male
Sex: Female, Male(Participants)Adalimumab
Female17
Male65
Region of Enrollment
Region of Enrollment(participants)Adalimumab
Canada82
08

Study locations

9 sites
  • Site Ref # / Investigator 74
    Calgary, Alberta T2N 4N1, Canada
  • Site Ref # / Investigator 70
    Edmonton, Alberta T6G 2S2, Canada
  • Site Ref # / Investigator 79
    Vancouver, British Columbia V5Z 1L7, Canada
  • Site Ref # / Investigator 64
    Winnipeg, Manitoba R3N OK6, Canada
  • Site Ref # / Investigator 78
    St. John's, Newfoundland and Labrador A1C 5B8, Canada
  • Site Ref # / Investigator 75
    Toronto, Ontario M4N 3M5, Canada
  • Site Ref # / Investigator 63
    Toronto, Ontario M5L 3L9, Canada
  • Site Ref # / Investigator 62
    Toronto, Ontario M5T 2S8, Canada
  • Site Ref # / Investigator 77
    Saskatoon, Saskatchewan S7K 0H6, Canada
09

References and documents

Publications

  • Revicki DA, Rentz AM, Luo MP, Wong RL. Psychometric characteristics of the short form 36 health survey and functional assessment of chronic illness Therapy-Fatigue subscale for patients with ankylosing spondylitis. Health Qual Life Outcomes. 2011 May 22;9:36. doi: 10.1186/1477-7525-9-36. PubMed 21600054 ↗
  • van der Heijde D, Salonen D, Weissman BN, Landewe R, Maksymowych WP, Kupper H, Ballal S, Gibson E, Wong R; Canadian (M03-606) study group; ATLAS study group. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther. 2009;11(4):R127. doi: 10.1186/ar2794. Epub 2009 Aug 24. PubMed 19703304 ↗
  • Lambert RG, Salonen D, Rahman P, Inman RD, Wong RL, Einstein SG, Thomson GT, Beaulieu A, Choquette D, Maksymowych WP. Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2007 Dec;56(12):4005-14. doi: 10.1002/art.23044. PubMed 18050198 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2003, a primary completion of Oct 2004 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2010, 5 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2005
First posted
Sep 20, 2005
Start
Dec 2003
Primary completionActual
Oct 2004
CompletionActual
Jun 2009
Results first posted
Apr 28, 2010
Last update
Jun 28, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00195819
Lead sponsor
Abbott
First posted
Sep 20, 2005
Start date
Dec 2003
Primary completion
Oct 2004
Completion
Jun 2009
Results posted
Apr 28, 2010
Last update
Jun 28, 2011

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion